Crestor Versus Placebo in Subjects With Heart Failure

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Heart Failure

Treatments

Drug: CRESTOR

Study type

Interventional

Funder types

Industry

Identifiers

NCT00206310

CORONA

D3562C00098

4522IL/0098

Details and patient eligibility

About

The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic symptomatic systolic heart failure of ischaemic aetiology as judged by the investigator, optimal therapy for chronic symptomatic systolic heart failure according to the investigator

Exclusion criteria

Acute myocardial infarction within 6 months before randomization
Treatment with any statin or other lipid lowering drug; or a medical condition that in the opinion of the investigator requires treatment with a statin or other lipid lowering drug